Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30644
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliams, Isabella Sc-
dc.contributor.authorPerera, Sachin-
dc.contributor.authorMurphy, Declan G-
dc.contributor.authorCorcoran, Niall M-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2022-
dc.date.accessioned2022-08-02T06:42:45Z-
dc.date.available2022-08-02T06:42:45Z-
dc.date.issued2022-07-25-
dc.identifier.citationBJU International 2022; 130(5): 580-581en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30644-
dc.language.isoeng-
dc.titleActive surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?en
dc.typeJournal Articleen
dc.identifier.journaltitleBJU internationalen
dc.identifier.affiliationDepartment of Urology and Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Australia..en
dc.identifier.affiliationEJ Whitten Prostate Cancer Research Centre at Epworth, Melbourne, Australia..en
dc.identifier.affiliationDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia..en
dc.identifier.affiliationUrologyen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35879832/en
dc.identifier.doi10.1111/bju.15860en
dc.type.contentTexten
dc.identifier.orcid0000-0002-4149-468Xen
dc.identifier.orcid0000-0002-7500-5899en
dc.identifier.orcid0000-0001-8553-5618en
dc.identifier.orcid0000-0002-5145-6783en
dc.identifier.pubmedid35879832-
local.name.researcherBolton, Damien M
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Nov 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.